{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5438","pValueComment":"One-sided significance level = 0.05","statisticalMethod":"t-test, 1 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.01","value":"-0.57"},{"groupId":"OG001","spread":"23.35","value":"-0.90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 Global Health Status score measures a cancer patient's perception of their overall health and well-being and ranges from 0 (worst) to 100 (best). A positive change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"MEAN","populationDescription":"Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had outcome measure data.","reportingStatus":"POSTED","timeFrame":"Baseline and 6 months from end of treatment. Treatment lasts 6-7 weeks.","title":"EORTC QLQ-C30 Global Health Status Score Change From Baseline at 6 Months From End of Treatment","type":"SECONDARY","unitOfMeasure":"score on a scale"}